Interleukin-1 beta targeted therapy for type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Interleukin-1 beta targeted therapy for type 2 diabetes. / Maedler, K.; Dharmadhikari, G.; Schumann, D.M.; Størling, Joachim.

In: Expert Opinion on Biological Therapy, Vol. 9, No. 9, 2009, p. 1177-1188.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Maedler, K, Dharmadhikari, G, Schumann, DM & Størling, J 2009, 'Interleukin-1 beta targeted therapy for type 2 diabetes', Expert Opinion on Biological Therapy, vol. 9, no. 9, pp. 1177-1188.

APA

Maedler, K., Dharmadhikari, G., Schumann, D. M., & Størling, J. (2009). Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opinion on Biological Therapy, 9(9), 1177-1188.

Vancouver

Maedler K, Dharmadhikari G, Schumann DM, Størling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opinion on Biological Therapy. 2009;9(9):1177-1188.

Author

Maedler, K. ; Dharmadhikari, G. ; Schumann, D.M. ; Størling, Joachim. / Interleukin-1 beta targeted therapy for type 2 diabetes. In: Expert Opinion on Biological Therapy. 2009 ; Vol. 9, No. 9. pp. 1177-1188.

Bibtex

@article{6903afd08b2e11df928f000ea68e967b,
title = "Interleukin-1 beta targeted therapy for type 2 diabetes",
abstract = "Since having been cloned in 1984, IL-1beta has been the subject of over 22,000 citations in Pubmed, among them over 800 reviews. This is because of its numerous effects. IL-1beta is a regulator of the body's inflammatory response and is produced after infection, injury, and antigenic challenge. It plays a role in various diseases, including autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases and type 1 diabetes, as well as in diseases associated with metabolic syndrome such as atherosclerosis, chronic heart failure and type 2 diabetes. Macrophage are the primary source of IL-1, but epidermal, epithelial, lymphoid and vascular tissues also synthesize IL-1. IL-1beta production and secretion have also been reported from pancreatic islets. Insulin-producing beta-cells within pancreatic islets are specifically prone to IL-beta-induced destruction and loss of function. Macrophage-derived IL-1beta production in insulin-sensitive organs, leads to progression of inflammation and induction of insulin resistance in obesity. We summarize the mechanisms involved in inflammation and specifically the IL-1beta signals that lead to the progression of insulin resistance and diabetes. We highlight recent clinical studies and experiments in animals and isolated islets using IL-1beta as a potential target for the therapy of type 2 diabetes Udgivelsesdato: 2009/9",
author = "K. Maedler and G. Dharmadhikari and D.M. Schumann and Joachim St{\o}rling",
note = "DA - 20090805IS - 1744-7682 (Electronic)IS - 1744-7682 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - ReviewRN - 0 (Interleukin-1beta)RN - 50-99-7 (Glucose)SB - IM",
year = "2009",
language = "English",
volume = "9",
pages = "1177--1188",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor & Francis",
number = "9",

}

RIS

TY - JOUR

T1 - Interleukin-1 beta targeted therapy for type 2 diabetes

AU - Maedler, K.

AU - Dharmadhikari, G.

AU - Schumann, D.M.

AU - Størling, Joachim

N1 - DA - 20090805IS - 1744-7682 (Electronic)IS - 1744-7682 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - ReviewRN - 0 (Interleukin-1beta)RN - 50-99-7 (Glucose)SB - IM

PY - 2009

Y1 - 2009

N2 - Since having been cloned in 1984, IL-1beta has been the subject of over 22,000 citations in Pubmed, among them over 800 reviews. This is because of its numerous effects. IL-1beta is a regulator of the body's inflammatory response and is produced after infection, injury, and antigenic challenge. It plays a role in various diseases, including autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases and type 1 diabetes, as well as in diseases associated with metabolic syndrome such as atherosclerosis, chronic heart failure and type 2 diabetes. Macrophage are the primary source of IL-1, but epidermal, epithelial, lymphoid and vascular tissues also synthesize IL-1. IL-1beta production and secretion have also been reported from pancreatic islets. Insulin-producing beta-cells within pancreatic islets are specifically prone to IL-beta-induced destruction and loss of function. Macrophage-derived IL-1beta production in insulin-sensitive organs, leads to progression of inflammation and induction of insulin resistance in obesity. We summarize the mechanisms involved in inflammation and specifically the IL-1beta signals that lead to the progression of insulin resistance and diabetes. We highlight recent clinical studies and experiments in animals and isolated islets using IL-1beta as a potential target for the therapy of type 2 diabetes Udgivelsesdato: 2009/9

AB - Since having been cloned in 1984, IL-1beta has been the subject of over 22,000 citations in Pubmed, among them over 800 reviews. This is because of its numerous effects. IL-1beta is a regulator of the body's inflammatory response and is produced after infection, injury, and antigenic challenge. It plays a role in various diseases, including autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases and type 1 diabetes, as well as in diseases associated with metabolic syndrome such as atherosclerosis, chronic heart failure and type 2 diabetes. Macrophage are the primary source of IL-1, but epidermal, epithelial, lymphoid and vascular tissues also synthesize IL-1. IL-1beta production and secretion have also been reported from pancreatic islets. Insulin-producing beta-cells within pancreatic islets are specifically prone to IL-beta-induced destruction and loss of function. Macrophage-derived IL-1beta production in insulin-sensitive organs, leads to progression of inflammation and induction of insulin resistance in obesity. We summarize the mechanisms involved in inflammation and specifically the IL-1beta signals that lead to the progression of insulin resistance and diabetes. We highlight recent clinical studies and experiments in animals and isolated islets using IL-1beta as a potential target for the therapy of type 2 diabetes Udgivelsesdato: 2009/9

M3 - Journal article

VL - 9

SP - 1177

EP - 1188

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -

ID: 20735923